<DOC>
	<DOC>NCT02706951</DOC>
	<brief_summary>This is a randomized, double-blind study comparing ABT-494 monotherapy to Methotrexate (MTX) monotherapy in subjects with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate treatment.</brief_summary>
	<brief_title>A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis of RA for &gt;= 3 months. Subjects must have been on oral or parenteral MTX therapy &gt;= 3 months and on a stable dose for &gt;= 4 weeks prior to first dose of study drug. Must have discontinued all conventional synthetic diseasemodifying antirheumatic drugs (csDMARDs) (other than MTX) &gt;= 4 weeks prior to first dose of study drug. Meets the following minimum disease activity criteria: &gt;= 6 swollen joints (based on 66 joint counts) and &gt;= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits. Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib). Prior exposure to any biological diseasemodifying antirheumatic drugs (bDMARDs). Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's Syndrome is permitted.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>anti-inflammatory agents</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>antirheumatic agents</keyword>
</DOC>